General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Innovative pricing

Price is just one of many factors affecting access to healthcare. We know that novel pricing models and generic medicines can help expand access, and both are part of our access programs.

Differential pricing for sustainable access

Differential pricing can help make medicines accessible — a treatment that is sold at full price in developed markets can be provided at a subsidized price in the poorest countries.

As part of our Malaria Initiative, Novartis provides its antimalarial medicine at not-for-profit prices for public sector use. Thanks to improvements in manufacturing efficiency, we have been able to reduce the treatment’s price by more than 50% since 2001.

Patents in least developed countries

Novartis was among the first healthcare companies to declare it would not patent medicines in the world’s poorest countries. In line with this commitment, Novartis does not file or maintain patents in any of the least developed countries. The United Nations defines these countries based on low gross national income, weak human assets (nutrition, health, education and adult literacy), and high level of economic vulnerability.

Novartis collaborates with the WHO, UNICEF, the Pan-American Health Organization (PAHO) and others to deliver vaccines against diseases such as diphtheria, tetanus and polio. As a part of this collaboration, Novartis supplies approximately 320 million doses of polio vaccine to UNICEF and PAHO annually for use in developing countries.

High-quality generic medicines

Generic medicines can expand access by offering affordable treatments with the same safety and efficacy after a patent expires.

Novartis is the only major healthcare company with leadership positions in both patented and generic pharmaceuticals. Our Sandoz Division is the second-largest producer of generics, with a global network covering 90% of the world.

Sandoz and its affiliate 1A Pharma often compete in tenders, where the lowest price product with the best delivery conditions usually wins the contract. 1A Pharma has successfully tendered bids in Zambia and Ghana, and plans to expand operations into other target countries, including Ethiopia and Cameroon.

Sandoz is the leader in biosimilars, Biosimilars are new versions of existing biopharmaceuticals whose patents have expired, with comparable safety and efficacy to the original product which helps improve access to biopharmaceuticals after patent expiry.

Read our positions on: